ALX ONCOLOGY HOLDINGS INC Insider Trading Activity

ALX Oncology Holdings (ALXO) reported an insider equity award for its Chief Financial Officer on a Form 4.

Accepted by SEC EDGAR 10/16/2025 - 12:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ALX Oncology Holdings (ALXO) reported an insider equity award for its Chief Financial Officer on a Form 4. The filing shows a grant of 198,750 employee stock options on 10/14/2025 with an exercise price of $1.7 per share and an expiration date of 10/14/2035. The grant was recorded at a price of $0 for the derivative security, indicating an award rather than a purchase.

The vesting schedule splits the award into two tranches: one-third vests on April 30, 2026, and the remaining two-thirds vest on October 31, 2026. Following the transaction, the filing lists 198,750 derivative securities beneficially owned, held directly.

Insider Trade Summary

Grant/Award: 198,750 shares

Grant/Award 1 txn

Insider Shantharam Harish

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	198,750	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 198,750 contracts (Direct)

Footnotes (1)

1. F1. One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ALXO disclose in this Form 4?

A grant of 198,750 employee stock options to the CFO on 10/14/2025.

What is the exercise price and expiration of the options?

The exercise price is $1.7 per share, expiring on 10/14/2035.

What is the vesting schedule for the CFO’s options at ALXO?

One-third vests on April 30, 2026; the remaining two-thirds vest on October 31, 2026.

How many derivative securities are beneficially owned after the transaction?

198,750 derivative securities, held directly.

Who is the reporting person and relationship to ALXO?

The reporting person is the company’s Chief Financial Officer.

Was this a purchase for cash?

No. The filing shows a derivative security price of $0, indicating a grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shantharam Harish

(Last) (First) (Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.7	10/14/2025		A		198,750		(1)	10/14/2035	Common Stock	198,750	$0	198,750	D

Explanation of Responses:

1. One-third of the shares subject to the option vest on April 30, 2026 and the remaining two-thirds of the option vest on October 31, 2026.

	/s/ Shelly Pinto, by power of attorney	10/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.